Therefore, AMD3100 serves as an accessory treatment in combination with G-CSF to induce a more effective mobilization for clinical use, especially in heavily G-CSF-pretreated patients with lymphoma and myeloma [33–35]. The gene discussed is CSF3; the disease is lymphoma.